Tandem Diabetes Care, Inc. · Healthcare · Medical Devices
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$25.29
−$0.50 (−1.96%) 4:00 PM ET
After hours$25.02
−$0.27 (−1.05%) 4:43 AM ET
Prev closePrevC$25.79
OpenOpen$25.81
Day highHigh$26.08
Day lowLow$24.96
VolumeVol1,745,028
Avg volAvgVol2,229,131
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.72B
P/E ratio
-8.26
FY Revenue
$1.01B
EPS
-3.06
Gross Margin
53.81%
Sector
Healthcare
AI report sections
MIXED
TNDM
Tandem Diabetes Care, Inc.
Tandem Diabetes Care exhibits strong recent price momentum with the stock up 36.2% over 1 month and 121.3% over 6 months, accompanied by heavy volume and multiple bullish technical signals, but momentum indicators are now in overbought territory. Fundamentally, the company delivers over $1.0 billion in trailing twelve‑month revenue and a solid 53.8% gross margin while facing persistent operating and net losses, negative free cash flow, and high return-on-equity pressure. Valuation ratios such as a high P/B multiple, negative EV/EBITDA, and a negative free cash flow yield combine with elevated short interest and predominantly negative legal‑related news flow, framing a profile of strong price action alongside notable fundamental and sentiment risks.
Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth Outlook
Tandem Diabetes Care (NASDAQ: TNDM) shares surged 33-37% following strong Q4 earnings results that beat expectations with adjusted loss of $0.01 vs. consensus loss of $0.08, and sales of $290.4M exceeding the $277M consensus. The company reported significant margin expansion with adjusted gross profit jumping from 51% to 58%, and adjusted operating profit of $8.3M versus a $30.2M loss year-ago. For 2026, the company forecasts sales of $1.065-$1.085B and expects 5-6% adjusted EBITDA margins, though slightly below consensus expectations. Management highlighted plans for double-digit pump shipment growth and a new pay-as-you-go model to improve profitability.
Strong earnings beat on both EPS and revenue, significant margin expansion (gross profit 51% to 58%), positive operating profit swing, optimistic management guidance for double-digit growth, and bullish technical positioning with stock up 33-37% and trading above key moving averages. Mixed technical signals (neutral RSI but bearish MACD) are outweighed by fundamental strength and analyst Buy rating.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims on behalf of Tandem Diabetes Care shareholders following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.
TNDMsecurities class actionmedical device correctioninsulin pumpshareholder lossesvoluntary recallstock decline
Sentiment note
The company issued a voluntary medical device correction for a critical product (insulin pump) that can cause discontinuation of insulin delivery, a serious safety issue. The stock declined 19.9% on the announcement, and the company is now facing a securities class action lawsuit alleging materially misleading business information was provided to investors.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.
TNDMsecurities class actionmedical device correctioninsulin pumpstock declineinvestor lossesvoluntary recall
Sentiment note
The company issued a voluntary medical device correction for a critical product (insulin pump) that can discontinue insulin delivery, resulting in a 19.9% stock price decline and triggering securities litigation investigation for allegedly issuing materially misleading business information.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. Investors who purchased TNDM securities may be eligible for compensation through a class action lawsuit.
TNDMsecurities class actionmedical device correctioninsulin pumpinvestor lossesmisleading business informationvoluntary recall
Sentiment note
The company issued a voluntary medical device correction for a critical product (insulin pump) that can discontinue insulin delivery, resulting in a 19.9% stock price decline and triggering a securities class action investigation for allegedly issuing materially misleading business information to investors.
NegativeGlobeNewswire Inc.• Rosen Law Firm
מידע למשקיעים ב-TNDM: אם סבלתם הפסדים בחברת Tandem Diabetes Care, Inc (נאסד"ק: TNDM), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי דין בנוגע לזכויותיכם
Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company disclosed materially misleading business information. On August 7, 2025, Tandem announced a voluntary recall of its t:slim X2 insulin pumps due to a potential speaker issue that could cause insulin delivery to stop. The stock declined 19.9% following the announcement. Investors who purchased Tandem securities may be eligible for compensation.
The company faces securities litigation for allegedly providing materially misleading information to investors. A voluntary recall of insulin pumps due to a critical safety issue (potential insulin delivery stoppage) triggered a 19.9% stock price decline, indicating significant loss of investor confidence and potential financial/reputational damage.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. The firm is preparing a class action lawsuit to recover investor losses.
TNDMsecurities class actionmedical device correctioninsulin pumpstock declineinvestor lossesvoluntary recall
Sentiment note
The company issued a voluntary medical device correction for a critical product (insulin pump) that can cause discontinuation of insulin delivery, a serious safety issue. The stock experienced a significant 19.9% decline following the announcement, and the company is now facing a securities class action lawsuit alleging materially misleading business information was provided to investors.
NegativeGlobeNewswire Inc.• Rosen Law Firm
ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE
Rosen Law Firm is encouraging investors in Skye Bioscience, SLM Corporation (Sallie Mae), and Tandem Diabetes Care to join securities class action lawsuits. The firm alleges that Skye Bioscience made materially false statements regarding the effectiveness and prospects of its drug nimacimab. Investors who purchased securities during specified class periods may be eligible for compensation, with a January 16, 2026 deadline to serve as lead plaintiff.
SKYESLMSLMBPTNDMsecurities class actioninvestor lawsuitmaterial misstatementlead plaintiff deadline
Sentiment note
Rosen Law Firm is investigating potential securities claims on behalf of shareholders, suggesting alleged violations and potential investor losses.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. The firm is preparing a class action lawsuit to recover investor losses.
The company issued a voluntary medical device correction for a critical product (insulin pump) that could discontinue insulin delivery, resulting in a 19.9% stock price decline and triggering a securities class action investigation for allegedly issuing materially misleading business information to investors.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. The firm is preparing a class action lawsuit to recover investor losses.
TNDMsecurities class actionmedical device correctioninsulin pumpstock declineinvestor lossesvoluntary recall
Sentiment note
The company issued a voluntary medical device correction for a critical product (insulin pump) that can discontinue insulin delivery, resulting in a 19.9% stock price decline and triggering securities litigation investigation for allegedly issuing materially misleading business information.
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused the stock to drop 19.9% on August 7, 2025.
Stock dropped 19.9% after announcing a voluntary medical device correction for t:slim X2 insulin pumps that could potentially interrupt insulin delivery, indicating significant product and financial risk
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused a significant stock price drop.
Company issued a voluntary medical device correction for t:slim X2 insulin pumps that triggered a 19.9% stock price decline, indicating potential product reliability issues and investor concern
NegativeGlobeNewswire Inc.• Rosen Law Firm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused a significant stock price drop.
Company issued a voluntary medical device correction for t:slim X2 insulin pumps that triggered a 19.9% stock price decline, indicating potential product reliability issues and investor concern
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
